KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Current Investments (2016 - 2026)

NovoCure's Cash & Current Investments history spans 13 years, with the latest figure at $432.0 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 53.5% to $432.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $432.0 million, a 53.5% decrease, with the full-year FY2025 number at $103.4 million, down 89.23% from a year prior.
  • Cash & Current Investments hit $432.0 million in Q1 2026 for NovoCure, up from $103.4 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for NVCR hit a ceiling of $969.4 million in Q4 2022 and a floor of $103.4 million in Q4 2025.
  • Historically, Cash & Current Investments has averaged $555.8 million across 5 years, with a median of $432.0 million in 2026.
  • Biggest five-year swings in Cash & Current Investments: surged 366.22% in 2024 and later crashed 89.23% in 2025.
  • Tracing NVCR's Cash & Current Investments over 5 years: stood at $969.4 million in 2022, then fell by 6.07% to $910.6 million in 2023, then increased by 5.41% to $959.9 million in 2024, then crashed by 89.23% to $103.4 million in 2025, then skyrocketed by 317.84% to $432.0 million in 2026.
  • Business Quant data shows Cash & Current Investments for NVCR at $432.0 million in Q1 2026, $103.4 million in Q4 2025, and $344.6 million in Q3 2025.